Clinical significance of antinuclear antibody positivity in patients with severe coronavirus disease 2019
暂无分享,去创建一个
J. Sohn | Sun Bean Kim | Y. Yoon | K. Yang | J. Kim | J. Suh | Sooyun Park
[1] O. Boyman,et al. Autoantibodies in COVID‐19 correlate with antiviral humoral responses and distinct immune signatures , 2022, medRxiv.
[2] A. Şener,et al. Antinuclear antibodies (ANAs) detected by indirect immunofluorescence (IIF) method in acute COVID-19 infection; future roadmap for laboratory diagnosis , 2021, Journal of Immunological Methods.
[3] T. Zewotir,et al. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients , 2021, BMC Infectious Diseases.
[4] Yu Kyung Kim,et al. Autoantibodies in moderate and critical cases of COVID‐19 , 2021, Clinical and translational science.
[5] Q. Lu,et al. COVID-19 and autoimmune diseases , 2020, Current opinion in rheumatology.
[6] Lisa Agatea,et al. SARS‐CoV‐2 infection as a trigger of autoimmune response , 2020, Clinical and translational science.
[7] M. Wener,et al. Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19) , 2020, Journal of Translational Autoimmunity.
[8] A. Esmaeilzadeh,et al. Immunobiology and immunotherapy of COVID‐19: A clinically updated overview , 2020, Journal of cellular physiology.
[9] N. Gebauer,et al. Clinical, Serological, and Histopathological Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD) , 2020, Frontiers in Immunology.
[10] A. Granito,et al. COVID‐19 and Immunological Dysregulation: Can Autoantibodies be Useful? , 2020, Clinical and translational science.
[11] Yindalon Aphinyanaphongs,et al. Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients With COVID-19 , 2020, Arteriosclerosis, thrombosis, and vascular biology.
[12] D. Siegel,et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study , 2020, The Lancet Rheumatology.
[13] L. Brammer,et al. Risk Factors for Intensive Care Unit Admission and In-hospital Mortality among Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] P. Meena,et al. COVID-19 and the kidney: A matter of concern , 2020, Current Medicine Research and Practice.
[15] D. Ragab,et al. The COVID-19 Cytokine Storm; What We Know So Far , 2020, Frontiers in Immunology.
[16] S. Dabernat,et al. Characterization of acute kidney injury in critically ill patients with severe coronavirus disease 2019 , 2020, Clinical kidney journal.
[17] P. Roux‐Lombard,et al. Antinuclear Antibodies With a Homogeneous and Speckled Immunofluorescence Pattern Are Associated With Lack of Cancer While Those With a Nucleolar Pattern With the Presence of Cancer , 2020, Frontiers in Medicine.
[18] Can Hou,et al. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID‐19 , 2020, Clinical and translational science.
[19] E. Schiffrin,et al. Hypertension and COVID-19 , 2020, American journal of hypertension.
[20] Lei Dong,et al. Kidney disease is associated with in-hospital death of patients with COVID-19 , 2020, Kidney International.
[21] M. Infantino,et al. European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist’s point of view , 2019, Annals of the Rheumatic Diseases.
[22] S. Aouadi,et al. Antinuclear antibodies in interstitial lung disease: Prevalence and clinical significance. , 2019, La Tunisie medicale.
[23] D. Gladman,et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus , 2019, Arthritis & rheumatology.
[24] Gheyath K Nasrallah,et al. Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms , 2019, Viruses.
[25] Sindhu R. Johnson,et al. The presence of anti-nuclear antibodies alone is associated with changes in B cell activation and T follicular helper cells similar to those in systemic autoimmune rheumatic disease , 2018, Arthritis Research & Therapy.
[26] T. Skare,et al. Anti‐nuclear antibodies in patients with breast cancer , 2018, Clinical and experimental immunology.
[27] T. Skare,et al. Antinuclear Antibodies and Rheumatoid Factor Positivity in Healthy Elderly Adults: A Cross‐Sectional Study in 336 Individuals , 2013, Journal of the American Geriatrics Society.
[28] F. Sciurba,et al. Autoantibodies in patients with chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.
[29] Shotai Kobayashi,et al. Antinuclear antibodies in healthy aging people: a prospective study , 1995, Mechanisms of Ageing and Development.
[30] J. Gold,et al. Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.
[31] J. Vermylen,et al. Diagnostic significance of antinuclear antibodies in neurologic patients , 1991, Acta neurologica Scandinavica.